Payment overview · 2025
General Payments
$448.72
24 reported records · 9 companies
Healthcare provider profile · identity verified
Lyndell D Scoles, MD
Allopathic & Osteopathic Physicians|Internal Medicine · COLUMBIA, MO · NPI 1689676231
Verified facts
What the public records show
CMS Open Payments records show Lyndell D Scoles, MD received $448.72 in general payments during 2025 across 24 reported records.
Amgen Inc. accounted for 35.0% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 14 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Eliquis, Paxlovid.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LUMIGAN as an associated drug or biological on 25016 records involving 7645 distinct recipient NPIs. Public Medicare Part D data also shows 16 claims for Lumigan by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 72 claims for Synthroid by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported BYETTA as an associated drug or biological on 60 records involving 49 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Byetta by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 16 claims for Farxiga by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ABRYSVO as an associated drug or biological on 55380 records involving 31565 distinct recipient NPIs. Public Medicare Part D data also shows 18 claims for Abrysvo by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 103 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PAXLOVID as an associated drug or biological on 24465 records involving 15715 distinct recipient NPIs. Public Medicare Part D data also shows 19 claims for Paxlovid by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Amgen Inc. | Unresolved — no canonical attribution shown | $157.25 | 35.0% | 8 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $87.68 | 19.5% | 5 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $57.83 | 12.9% | 3 | 2025 |
| Globus Medical, Inc. | Unresolved — no canonical attribution shown | $40.75 | 9.1% | 2 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $32.07 | 7.2% | 2 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $24.07 | 5.4% | 1 | 2025 |
| Neurelis, Inc. |
Neurelis, Inc. exact · evidence 2025-02-20 |
$18.64 | 4.2% | 1 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $15.35 | 3.4% | 1 | 2025 |
| Radius Health, Inc. | Unresolved — no canonical attribution shown | $15.08 | 3.4% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $448.72 | 24 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| EVENITY Normalized: evenity |
Biological | Amgen Inc. | $128.83 | 6 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $65.38 | 4 | 2025 |
Source payment records
|
|||||
| Senza Normalized: senza |
Device | Globus Medical, Inc. | $40.75 | 2 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $36.49 | 2 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $33.18 | 2 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | PFIZER INC. | $32.20 | 2 | 2025 |
Source payment records
|
|||||
| KRYSTEXXA Normalized: krystexxa |
Biological | Amgen Inc. | $28.42 | 2 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $24.07 | 1 | 2025 |
Source payment records
|
|||||
| PAXLOVID Normalized: paxlovid |
Drug | PFIZER INC. | $22.30 | 1 | 2025 |
Source payment records
|
|||||
| VALTOCO Normalized: valtoco |
Drug | Neurelis, Inc. | $18.64 | 1 | 2025 |
Source payment records
|
|||||
| The Cologuard Plus Collection Kit Normalized: the cologuard plus collection kit |
Device | Exact Sciences Corporation | $16.85 | 1 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $15.35 | 1 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $15.22 | 1 | 2025 |
Source payment records
|
|||||
| Tymlos Normalized: tymlos |
Drug | Radius Health, Inc. | $15.08 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 103 | exact normalized | Medicare Part D |
| PAXLOVID paxlovid |
2025 | Paxlovid | 2024 | 19 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LUMIGAN open payments reported associated product |
CMS Open Payments — General Payments 25016 supporting records · 7645 recipient NPIs · example record 1201352548 |
Lumigan · 2024 Exact normalized brand match · 1 Part D row |
16 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
72 | 18 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | BYETTA open payments reported associated product |
CMS Open Payments — General Payments 60 supporting records · 49 recipient NPIs · example record 1206154618 |
Byetta · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
16 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ABRYSVO open payments reported associated product |
CMS Open Payments — General Payments 55380 supporting records · 31565 recipient NPIs · example record 1228794147 |
Abrysvo · 2024 Exact normalized brand match · 1 Part D row |
18 | 18 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
103 | 24 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | PAXLOVID open payments reported associated product |
CMS Open Payments — General Payments 24465 supporting records · 15715 recipient NPIs · example record 1228794432 |
Paxlovid · 2024 Exact normalized brand match · 1 Part D row |
19 | 19 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Levothyroxine Sodium | Levothyroxine Sodium | 532 | 131 |
| Atorvastatin Calcium | Atorvastatin Calcium | 440 | 113 |
| Amlodipine Besylate | Amlodipine Besylate | 284 | 69 |
| Pantoprazole Sodium | Pantoprazole Sodium | 268 | 71 |
| Allopurinol | Allopurinol | 217 | 55 |
| Omeprazole | Omeprazole | 180 | 53 |
| Lisinopril | Lisinopril | 155 | 40 |
| Losartan Potassium | Losartan Potassium | 153 | 40 |
| Azithromycin | Azithromycin | 149 | 105 |
| Meloxicam | Meloxicam | 144 | 40 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 138 | 35 |
| Metformin Hcl Er | Metformin Hcl | 123 | 32 |
| Donepezil Hcl | Donepezil Hcl | 119 | 28 |
| Simvastatin | Simvastatin | 116 | 31 |
| Hydrochlorothiazide | Hydrochlorothiazide | 114 | 28 |
| Potassium Chloride | Potassium Chloride | 114 | 32 |
| Liothyronine Sodium | Liothyronine Sodium | 112 | 27 |
| Eliquis | Apixaban | 103 | 24 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 101 | 27 |
| Tamsulosin Hcl | Tamsulosin Hcl | 99 | 25 |
| Furosemide | Furosemide | 98 | 24 |
| Metformin Hcl | Metformin Hcl | 93 | 25 |
| Escitalopram Oxalate | Escitalopram Oxalate | 91 | 22 |
| Alprazolam | Alprazolam | 88 | 23 |
| Montelukast Sodium | Montelukast Sodium | 86 | 17 |
| Gabapentin | Gabapentin | 85 | 19 |
| Metoprolol Tartrate | Metoprolol Tartrate | 85 | 17 |
| Tramadol Hcl | Tramadol Hcl | 85 | 25 |
| Spironolactone | Spironolactone | 82 | 21 |
| Clonazepam | Clonazepam | 80 | 17 |
| Synthroid | Levothyroxine Sodium | 72 | 18 |
| Zolpidem Tartrate | Zolpidem Tartrate | 62 | 26 |
| Metoprolol Succinate | Metoprolol Succinate | 61 | 21 |
| Sertraline Hcl | Sertraline Hcl | 60 | 18 |
| Irbesartan | Irbesartan | 59 | 16 |
| Methylprednisolone | Methylprednisolone | 58 | 39 |
| Finasteride | Finasteride | 57 | 16 |
| Carvedilol | Carvedilol | 55 | 11 |
| Citalopram Hbr | Citalopram Hydrobromide | 53 | 14 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 50 | 13 |
| Clopidogrel | Clopidogrel Bisulfate | 49 | 13 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 48 | suppressed |
| Pregabalin | Pregabalin | 48 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 47 | 30 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 45 | suppressed |
| Estradiol | Estradiol | 45 | 14 |
| Fluoxetine Hcl | Fluoxetine Hcl | 42 | suppressed |
| Testosterone Cypionate | Testosterone Cypionate | 42 | suppressed |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 41 | 23 |
| Duloxetine Hcl | Duloxetine Hcl | 39 | suppressed |
| Lorazepam | Lorazepam | 39 | 12 |
| Nebivolol Hcl | Nebivolol Hcl | 39 | 15 |
| Prednisone | Prednisone | 38 | 20 |
| Doxycycline Hyclate | Doxycycline Hyclate | 37 | 28 |
| Ezetimibe | Ezetimibe | 37 | suppressed |
| Celecoxib | Celecoxib | 35 | 11 |
| Ozempic | Semaglutide | 35 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 33 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 31 | suppressed |
| Xarelto | Rivaroxaban | 30 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 29 | 16 |
| Diclofenac Potassium | Diclofenac Potassium | 29 | suppressed |
| Fluticasone Propionate | Fluticasone Propionate | 28 | suppressed |
| Glipizide Er | Glipizide | 28 | suppressed |
| Nystatin | Nystatin | 28 | 11 |
| Terbinafine Hcl | Terbinafine Hcl | 28 | 12 |
| Valacyclovir | Valacyclovir Hcl | 28 | 16 |
| Mounjaro | Tirzepatide | 27 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 26 | 19 |
| Acyclovir | Acyclovir | 25 | 11 |
| Glimepiride | Glimepiride | 25 | suppressed |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 25 | suppressed |
| Carisoprodol | Carisoprodol | 24 | suppressed |
| Febuxostat | Febuxostat | 24 | suppressed |
| Valsartan | Valsartan | 24 | suppressed |
| Atenolol | Atenolol | 23 | suppressed |
| Bupropion Xl | Bupropion Hcl | 23 | suppressed |
| Cefuroxime | Cefuroxime Axetil | 22 | suppressed |
| Famotidine | Famotidine | 22 | suppressed |
| Fentanyl | Fentanyl | 22 | suppressed |
| Fluconazole | Fluconazole | 22 | 11 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 22 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 22 | suppressed |
| Premarin | Estrogens, Conjugated | 22 | suppressed |
| Ultra-Fine Mini Pen Needle | Pen Needle, Diabetic | 22 | suppressed |
| Arexvy | Rsvpref3 Antigen/As01e/Pf | 21 | 21 |
| Cephalexin | Cephalexin | 21 | suppressed |
| Digoxin | Digoxin | 20 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 20 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 19 | suppressed |
| Bumetanide | Bumetanide | 19 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 19 | 19 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 19 | suppressed |
| Abrysvo | Rsv Vacc, Pref A And Pref B/Pf | 18 | 18 |
| Diclofenac Sodium | Diclofenac Sodium | 18 | suppressed |
| Topiramate | Topiramate | 18 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 17 | suppressed |
| Entresto | Sacubitril/Valsartan | 17 | suppressed |
| Metronidazole | Metronidazole | 17 | suppressed |
| Mirtazapine | Mirtazapine | 17 | suppressed |
| Trazodone Hcl | Trazodone Hcl | 17 | suppressed |
| Calcitonin-Salmon | Calcitonin,salmon,synthetic | 16 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 16 | suppressed |
| Felodipine Er | Felodipine | 16 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 16 | suppressed |
| Lidocaine | Lidocaine | 16 | suppressed |
| Lumigan | Bimatoprost | 16 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 15 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 15 | suppressed |
| Testosterone | Testosterone | 15 | suppressed |
| Ketoconazole | Ketoconazole | 14 | suppressed |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 14 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 14 | suppressed |
| Rabeprazole Sodium | Rabeprazole Sodium | 14 | suppressed |
| Raloxifene Hcl | Raloxifene Hcl | 14 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 14 | suppressed |
| Temazepam | Temazepam | 14 | suppressed |
| Trulicity | Dulaglutide | 14 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 13 | suppressed |
| Aripiprazole | Aripiprazole | 13 | suppressed |
| Folic Acid | Folic Acid | 13 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 13 | suppressed |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 13 | suppressed |
| Pitavastatin Calcium | Pitavastatin Calcium | 13 | suppressed |
| Pravastatin Sodium | Pravastatin Sodium | 13 | suppressed |
| Byetta | Exenatide | 12 | suppressed |
| Colchicine | Colchicine | 12 | suppressed |
| Fluvoxamine Maleate | Fluvoxamine Maleate | 12 | suppressed |
| Memantine Hcl | Memantine Hcl | 12 | suppressed |
| Propranolol Hcl Er | Propranolol Hcl | 12 | suppressed |
| Bisoprolol Fumarate | Bisoprolol Fumarate | 11 | suppressed |
| Glyxambi | Empagliflozin/Linagliptin | 11 | suppressed |
| Ibuprofen | Ibuprofen | 11 | suppressed |
| Jardiance | Empagliflozin | 11 | suppressed |
| Niacin Er | Niacin | 11 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $448.72 · 24 records | Amgen Inc. | BREZTRI, Cologuard Collection Kit, ELIQUIS, EVENITY, KRYSTEXXA, Kerendia, NURTEC ODT, PAXLOVID, Senza, The Cologuard Plus Collection Kit, Tymlos, UBRELVY, VALTOCO, ZAVZPRET | 7 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Eliquis play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error